Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Ingela Franck-Lissbrant"'
Autor:
Giuseppe Fallara, Ingela Franck Lissbrant, Johan Styrke, Francesco Montorsi, Hans Garmo, Pär Stattin
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0244462 (2020)
IntroductionThe aim of this study was to assess time on treatment with abiraterone and enzalutamide, two androgen receptor targeted (ART) drugs, the impact on time on treatment of time interval without drug supply between prescription fillings, and a
Externí odkaz:
https://doaj.org/article/46007994ce514c949089f6d0f72bc993
Autor:
Walter Cazzaniga, Eugenio Ventimiglia, Massimo Alfano, David Robinson, Ingela Franck Lissbrant, Stefan Carlsson, Johan Styrke, Francesco Montorsi, Andrea Salonia, Pär Stattin
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Given the increasing prevalence of cancer, it is vital to systematically collect data in order to monitor disease trends and quality of cancer care. For this purpose, clinical cancer registries have been developed in some countries. These registers a
Externí odkaz:
https://doaj.org/article/60346305e1234969aee943fd14e68fca
Autor:
Oskar Bergengren, Christian Corsini, Stefan Carlsson, Ingela Franck-Lissbrant, Hans Garmo, Marie Hjelm-Eriksson, Per Fransson, Jon Kindblom, David Robinson, Marcus Westerberg, Pär Stattin, Sigrid Carlsson
Publikováno v:
Journal of Urology. 209
Publikováno v:
Cancers, Vol 13, Iss 4, p 875 (2021)
Real-world data (RWD), that is, data from sources other than controlled clinical trials, play an increasingly important role in medical research. The development of quality clinical registers, increasing access to administrative data sources, growing
Externí odkaz:
https://doaj.org/article/4979c7b88acd4e06a55b5d325670f3c3
Autor:
Charlotte Alverbratt, Hanna Vikman, Marie Hjälm Eriksson, Pär Stattin, Ingela Franck Lissbrant
Publikováno v:
Scandinavian Journal of Urology. 56:95-101
Background Patients with advanced prostate cancer (PCa) typically undergo numerous lines of treatment leading to large amounts of information in Electronic Health Records (EHRs). The Patient-overview Prostate Cancer (PPC) presents clinical informatio
Autor:
Pär Stattin, Hans Garmo, Camilla Thellenberg-Karlsson, Giuseppe Fallara, Johan Styrke, Ingela Franck Lissbrant, Rolf Gedeborg
Publikováno v:
Journal of Urology. 207
Autor:
Suzanne Kilany, Ingela Franck Lissbrant, Karin Fagerlund, Johanna Svensson, Pär Stattin, Oskar Gauffin, Marie Hjälm-Eriksson
Publikováno v:
Scandinavian Journal of Urology. 55:1-8
To investigate time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer in Sweden, and the associated health economic impact.Registry study (NCT03619980) of the Prostate Cancer data Base Sweden with
Autor:
Rolf, Gedeborg, Hans, Garmo, Camilla, Thellenberg-Karlsson, Giuseppe, Fallara, Johan, Styrke, Ingela, Franck Lissbrant, Pär, Stattin
Publikováno v:
Acta oncologica (Stockholm, Sweden). 61(3)
Autor:
Rolf Gedeborg, Hans Garmo, Camilla Thellenberg-Karlsson, Giuseppe Fallara, Johan Styrke, Ingela Franck Lissbrant, Pär Stattin
Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a59b8e31f386166d0402544fcf9041e8
Autor:
Ingela Franck Lissbrant, Marcus Westerberg, Hans Garmo, Jan-Erik Damber, Pär Stattin, David Robinson
Publikováno v:
Acta Oncologica. 59:106-111
Background: There have been large changes in the pattern of detection, work-up and treatment of men with prostate cancer during the last two decades. Therefore, we aimed to investigate temporal changes in survival in men with metastatic prostate canc